SignalFDA/Bio

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy

Licensing deal with GSK validates HUTCHMED's KRAS-EGFR antibody conjugate pipeline.

What changed

Licensing deal with GSK validates HUTCHMED's KRAS-EGFR antibody conjugate pipeline.

Why it matters

Licensing deal with GSK validates HUTCHMED's KRAS-EGFR antibody conjugate pipeline. — impact context not separately stored; see What changed.

Sources